Who
David Lemus
Director
Company insider
Files Form 4 as: Director, Silence Therapeutics; Director, Scilex Holding; Director, Sorrento Therapeutics.
In numbers
- Trades disclosed
- 11
- Buys
- 1
- Sells
- 0
- Bought
- $1,800
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 14 Nov 2017
- Last trade
- 2 Jan 2026
- Last filed
- 6 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jan 2026filed 6 Jan 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,000 at $0.00 | filing |
| 17 Oct 2024filed 18 Oct 2024 | SCLX Scilex HoldingPharmaceuticals | SEC FORM 4 Bought | $1,8002,000 at $0.90 | filing |
| 15 Mar 2024filed 26 Jun 2024 | SCLX Scilex Holdingoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 17 Jan 2023filed 17 Jan 2023 | SCLX Scilex Holdingoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 30 Aug 2021filed 30 Aug 2021 | Sorrento Therapeuticsoption or derivative | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 15 Jun 2020filed 15 Jun 2020 | Sorrento Therapeuticsoption or derivative | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 19 Apr 2019filed 23 Apr 2019 | Sorrento Therapeuticsoption or derivative | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 26 Nov 2018filed 27 Nov 2018 | Sorrento Therapeuticsoption or derivative | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 14 Nov 2017filed 16 Nov 2017 | Sorrento Therapeuticsoption or derivative | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
News
Head-To-Head Contrast: Scilex (NASDAQ:SCLX) versus Eli Lilly and Company (NYSE:LLY)SCLX · themarketsdaily.com · 9 Oct 2026Contrasting Enanta Pharmaceuticals (NASDAQ:ENTA) and Scilex (NASDAQ:SCLX)SCLX · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name David Lemus; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.